SACOMITATUG DERUXTECAN
UNII YC3FM28QGU

Substance Identification & Data

This profile provides standardized clinical and technical data for Sacomitatug Deruxtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) YC3FM28QGU.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3055975-39-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

YC3FM28QGU

CAS Registry Number

3055975-39-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

SACOMITATUG DERUXTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

13861

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Sacomitatug Deruxtecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Sacomitatug Deruxtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Sacomitatug Deruxtecan

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-447) [VH (Homo sapiens IGHV3-72*01 (85.0%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.10.8] (26-33.51-60.99-106)) (1-117) -Homo sapiens IGHG1*07 (100%) G1m17, G1m1, G1m2 CH1 K120, CH3 D12, L14, G110 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 (231-340), CH3 D12 (356), L14 (358), G110 (431) (341-445), CHS (446-447)) (118-447)], (220-219')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (Homo sapiens IGKV2-28*01 (86.0%) -IGKJ1*01 (100%), CDR-IMGT [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (226-226'':229-229'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; substituted at the sulfur atoms of an average of eight L-cysteinyl residues among 220, 226, 229, 219', 220'', 226'', 229'' and 219''' with (3RS)-1-[(10S)-10-benzyl-1-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-1,6,9,12,15,18-hexaoxo-3-oxa-5,8,11,14,17-pentaazatricosan-23-yl]-2,5-dioxopyrrolidin-3-yl (deruxtecan) groups

Immunoglobulin G1, anti-(human mucin 1) (human-Mus musculus monoclonal MADP-6301a γ1-chain), complex with human-Mus musculus monoclonal MADP-6301a κ-chain, dimer, octakis(thioether)with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide

immunoglobulin G1-kappa, anti-[Homo sapiens MUC1 (mucin 1, polymorphic epithelial mucin, PEM, CD227)], humanized monoclonal antibody, conjugated on an average of eight cysteinyl residues to deruxtecan, comprising a linker and a camptothecin derivative (sacomitatug deruxtecan)

sacomitatug deruxtecan [INN]

External Clinical & Regulatory Resources

Previous UNIIYC38073CRY

Next UNIIYC3R3P68S2